A Layer Plus Approach to Implementation Research and Collaboration for Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention.
In 2020, the HIV prevention clinical trials, HPTN (HIV Prevention Trials Network) 083 and 084, reported that long-acting injectable cabotegravir (CAB-LA) for HIV prevention was statistically superior to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (Pr...
| Publicado en: | Health Promotion Practice Vol. 23; no. 6; pp. 912 - 916 |
|---|---|
| Autores principales: | , , |
| Formato: | pictorial Journal Article |
| Publicado: |
Sage Publications Inc.
Nov2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=160562798&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 160562798 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15248399 IS2 jtl: Health Promotion Practice issn: 15248399 maglogo: Y pubinfo: dt: Nov2022 vid: 23 iid: 6 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 160562798 157538038 160562798 160562798 10.1177/15248399211053584 160562798 ppf: 912 ppct: 4 formats: tig: atl: A Layer Plus Approach to Implementation Research and Collaboration for Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention. aug: au: Pilgrim, Nanlesta A. Evans, Tammeka M. Czarnogorski, Maggie affil: ViiV Healthcare, Research Triangle Park, NC, USA sug: subj: Research, Medical Collaboration Pre-Exposure Prophylaxis Utilization Antiviral Agents Administration and Dosage Injections HIV Infections Prevention and Control Implementation Science Health Services Accessibility Health Promotion Methods Pre-Exposure Prophylaxis Methods Sexual and Gender Minorities World Health HIV Education Sexual Health ab: In 2020, the HIV prevention clinical trials, HPTN (HIV Prevention Trials Network) 083 and 084, reported that long-acting injectable cabotegravir (CAB-LA) for HIV prevention was statistically superior to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in cisgender men and transgender women who have sex with men, and cisgender women. However, clinical efficacy does not translate to real-world effectiveness and clinical practice as evidenced by current global use of oral PrEP. There are ~626,000 users of PrEP, which is significantly below the 3 million goal set by UNAIDS for 2020. Implementation will be key to ensuring that CAB-LA reaches those who desire to use it. We describe the Layer Plus Approach for CAB-LA for PrEP dissemination and implementation. The "Layer" is focused on integrating CAB-LA into existing PrEP models of care and understanding the best delivery channels that could be established in existing programs. Important implications of layering include preparing health professionals to provide CAB-LA, improving access for potential users, and addressing existing PrEP structural and facility barriers. "Plus," which accounts for the existing disparities in PrEP access and use, means expanding CAB-LA to reach individuals for whom HIV prevention options have not been accessible or who have lapsed on oral PrEP. Implications for Plus include the development of new structures, systems, policies, and processes. A key aspect to the Approach is building collaborations to aid successful implementation. The Layer Plus Approach is a simple but strategic framework or a tailored approach to guide dissemination research and implementation. pubtype: Academic Journal doctype: pictorial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|